Lexaria Bioscience Corp. (LEXX) DCF Valuation

Lexaria Bioscience Corp. (LEXX) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Lexaria Bioscience Corp. (LEXX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Whether you're an investor or analyst, this (LEXX) DCF Calculator is your go-to resource for accurate valuation. Equipped with real data from Lexaria Bioscience Corp., you can adjust forecasts and observe the effects in real time.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue .4 .7 .3 .2 .5 .6 .8 1.0 1.2 1.6
Revenue Growth, % 0 87.95 -64.66 -11.43 105.24 27.96 27.96 27.96 27.96 27.96
EBITDA -4.0 -5.6 -6.5 -6.4 -5.7 -.6 -.8 -1.0 -1.2 -1.6
EBITDA, % -1040.9 -771.39 -2551.45 -2824.23 -1222.75 -100 -100 -100 -100 -100
Depreciation .1 .1 .1 .1 .1 .2 .3 .4 .5 .6
Depreciation, % 37.99 20.42 57.52 64.28 16.4 39.32 39.32 39.32 39.32 39.32
EBIT -4.1 -5.7 -6.7 -6.5 -5.8 -.6 -.8 -1.0 -1.2 -1.6
EBIT, % -1078.89 -791.81 -2608.97 -2888.5 -1239.16 -100 -100 -100 -100 -100
Total Cash 1.3 11.8 6.2 1.5 6.6 .6 .8 1.0 1.2 1.6
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .3 .3 .2 .2 .2
Account Receivables, % 81.64 47.38 79.01 77.47 33.27
Inventories .1 .0 .0 .0 .0 .1 .1 .1 .1 .2
Inventories, % 30.39 4.1 15.04 0 0 9.91 9.91 9.91 9.91 9.91
Accounts Payable .0 .1 .0 .2 1.1 .3 .3 .4 .6 .7
Accounts Payable, % 11.72 8.29 10.12 99.48 227.86 45.92 45.92 45.92 45.92 45.92
Capital Expenditure .0 -.1 -.1 -.2 .0 -.2 -.2 -.3 -.4 -.5
Capital Expenditure, % -8.75 -11 -51.47 -74.98 -9.26 -31.09 -31.09 -31.09 -31.09 -31.09
Tax Rate, % 0.22912 0.22912 0.22912 0.22912 0.22912 0.22912 0.22912 0.22912 0.22912 0.22912
EBITAT -4.1 -3.4 -6.6 -6.5 -5.7 -.5 -.7 -.9 -1.1 -1.5
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -4.4 -3.3 -6.4 -6.2 -4.9 -1.6 -.7 -.9 -1.1 -1.4
WACC, % 9.41 9.4 9.41 9.41 9.41 9.41 9.41 9.41 9.41 9.41
PV UFCF
SUM PV UFCF -4.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -1
Terminal Value -20
Present Terminal Value -12
Enterprise Value -17
Net Debt -6
Equity Value -10
Diluted Shares Outstanding, MM 12
Equity Value Per Share -0.84

What You Will Get

  • Authentic Lexaria Data: Preloaded financials – covering everything from revenue to EBIT – based on actual and projected figures.
  • Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
  • Immediate Valuation Updates: Automatic recalculations to assess the impact of changes on Lexaria’s fair value.
  • Flexible Excel Template: Designed for quick edits, scenario analysis, and detailed forecasts.
  • Efficient and Precise: Bypass the hassle of building models from the ground up while ensuring accuracy and adaptability.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Lexaria Bioscience Corp. (LEXX).
  • WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to LEXX.
  • Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates as needed for Lexaria.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Lexaria Bioscience Corp. (LEXX).
  • Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.

How It Works

  • 1. Download the Template: Obtain and open the Excel file containing Lexaria Bioscience Corp.'s (LEXX) preloaded data.
  • 2. Modify Key Inputs: Adjust critical assumptions such as growth projections, WACC, and capital investments.
  • 3. Analyze Results in Real-Time: The DCF model automatically computes intrinsic value and NPV based on your inputs.
  • 4. Explore Different Scenarios: Evaluate various forecasts to understand a range of valuation possibilities.
  • 5. Present with Assurance: Deliver professional valuation analyses to enhance your decision-making process.

Why Choose Lexaria Bioscience Corp. (LEXX)?

  • Innovation: Pioneering advancements in cannabinoid delivery technology.
  • Research-Driven: Backed by extensive scientific studies and clinical trials.
  • Market Potential: Positioned in a rapidly growing industry with significant opportunities.
  • Experienced Leadership: Led by a team with deep expertise in biotech and pharmaceuticals.
  • Commitment to Quality: Focused on high standards in product development and manufacturing.

Who Should Use This Product?

  • Investors: Evaluate Lexaria Bioscience Corp.'s (LEXX) market potential before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts for Lexaria.
  • Startup Founders: Understand the valuation strategies of innovative biotech companies like Lexaria.
  • Consultants: Create comprehensive valuation reports tailored for clients interested in Lexaria Bioscience Corp. (LEXX).
  • Students and Educators: Utilize current data to explore and teach valuation principles in the biotech sector.

What the Lexaria Bioscience Template Contains

  • Preloaded LEXX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.